HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons

HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons

The review analyzes the potential advantages and problems associated with using HIF prolyl hydroxylase inhibitors as a treatment for COVID-19. HIF prolyl hydroxylase inhibitors are known to boost endogenous erythropoietin (Epo) and activate erythropoiesis by stabilizing and activating the hypoxia in...

Full description

Bibliographic Details
Main Authors: Andrey A. Poloznikov, Stepan A. Nersisyan, Dmitry M. Hushpulian, Eliot H. Kazakov, Alexander G. Tonevitsky, Sergey V. Kazakov, Valery I. Vechorko, Sergey V. Nikulin, Julia A. Makarova, Irina G. Gazaryan
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-01-01
Series:Frontiers in Pharmacology
Subjects:
SARS-CoV
hypoxia inducible factor
roxadustat
vadadustat
adaptaquin
neuradapt
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2020.621054/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2020.621054/full

Similar Items